Basilea Pharmaceutica Ltd. said it filed a New Drug Submission (NDS) for alitretinoin with the Therapeutic Products Directorate of Health Canada.
The submission supports the proposed use of oral alitretinoin in severe refractory chronic hand eczema. Marketing applications for the use of alitretinoin in the treatment of severe chronic refractory hand eczema have also been filed in Switzerland and in several EU member states.
Basilea Pharmaceutica Ltd. is an integrated biopharmaceutical company headquartered in Basel, Switzerland. Basilea is currently focused on the research, development and commercialisation of new antibacterial, antifungal and dermatology drugs in the hospital and specialty care setting.